Trump Quietly Adds Medical Cannabis Protections to Federal Budget for First Time

In a move that honestly surprised a lot of cannabis industry watchers, President Trump's FY2026 federal budget proposal includes continued funding for the Rohrabacher-Blumenauer amendment — the rider that prevents the Department of Justice from interfering with state medical cannabis laws.

Here's the thing: this is actually a reversal from Trump's earlier budget proposal for FY2026, which specifically requested that the rider be deleted. Now, in the updated proposal, he's protecting it. Quietly. Without a big announcement or press conference. Just... included in the budget.

This is a legitimate shift in policy direction, and while it's not the earth-shattering moment that full federal legalization would be, it matters for medical cannabis patients across the country. Let's break down what's happening, why it's significant, and what it means for the future of cannabis policy.

What Is the Rohrabacher-Blumenauer Amendment, Anyway?

If you've been following cannabis policy for more than five minutes, you've probably heard this name. The Rohrabacher-Blumenauer amendment (originally called the Rohrabacher-Farr amendment) has been the legal shield protecting medical cannabis programs in states like California, Colorado, Oregon, New York, and others since 2014.

Here's the core of what it does: it prevents the Department of Justice from using any federal funds to prosecute people engaged in medical cannabis activities that are legal under state law. That's it. That's the protection.

Without this rider, the federal government — in theory — could:

• Raid legal state cannabis dispensaries
• Prosecute medical cannabis patients in states where it's legal
• Shut down state-authorized growing operations
• Interfere with interstate commerce related to medical cannabis

With the rider, federal prosecutors can't use their budget allocation to mess with your state's legal medical cannabis program. It's like a small legal barrier between federal law and state law.

It's been renewed in every federal spending bill since 2014. Becoming standard practice. No drama, no controversy most years. Just... in the budget.

Until recently.

The Recent Shake-Up: Trump's FY2026 Proposal

Earlier this year, when Trump's FY2026 budget proposal was first released, it included language requesting that Congress REPEAL the Rohrabacher-Blumenauer amendment. This was notable because it represented a potential reversal of protections that had been in place for over a decade.

For medical cannabis patients and the legal industry in states with robust medical programs, that was concerning. If the amendment was repealed, suddenly the legal ground beneath medical cannabis dispensaries, growers, and patients could shift dramatically.

This sparked conversation in industry circles, policy discussions, and probably some nervous meetings in state cannabis offices across the country.

But then something shifted.

The Reversal: Protection Included in Budget

In the updated budget proposal (the one we're looking at now), the Rohrabacher-Blumenauer amendment is actually included — meaning the Trump administration is now supporting its continuation. Not just allowing it passively, but actively including it in the budget proposal.

This is genuinely confusing messaging from a communications perspective. You don't typically ask Congress to delete something and then immediately turn around and protect it. It suggests internal debate, maybe pressure from industry advocates or Republican medical cannabis supporters, or just a change of direction that didn't get clearly explained to the public.

What matters is: the protection is in the current budget proposal. Medical cannabis patients and operators in legal states can breathe a little easier. At least for this budget cycle.

The DEA Rescheduling Plot Thickens

Here's where things get weird. While Trump's budget is protecting medical cannabis programs, the DEA rescheduling process — which Trump initiated with an executive order — still remains "pending."

Roger Stone, a longtime Trump associate and cannabis advocate, recently claimed that someone is "holding up" the rescheduling process. The exact quote was something like someone is deliberately stalling it, preventing progress on Trump's stated goal of rescheduling cannabis.

This creates a confusing picture: Trump is protecting medical cannabis in the budget while simultaneously... not pushing rescheduling through as aggressively as he promised?

Rescheduling cannabis (moving it from Schedule I to Schedule III or lower) would be a bigger deal than protecting state medical programs. It would allow for federal research, would change how the IRS and pharmaceutical companies approach cannabis, and would be a significant federal-level acknowledgment that cannabis has medical value.

But it's still pending. Still stalled. The exact mechanics of why are unclear, but Stone's claim suggests internal disagreement or bureaucratic resistance.

FBI Memo: Agents Can Now Invest in Hemp and CBD

In related news, the FBI released guidance allowing its agents to invest in hemp and CBD businesses. This is actually huge symbolically.

The FBI — traditionally one of the more restrictive federal agencies on cannabis issues — is essentially saying its employees can have financial interests in hemp and CBD companies. This represents a dramatic shift in how federal law enforcement views the cannabis and hemp industries.

It's not authorization for agents to own a dispensary, but it shows institutional recognition that hemp and CBD businesses are legitimate, regulated industries where federal employees can have investments without creating conflicts of interest.

CMS Finalizes Medicare Advantage Hemp Coverage

The Centers for Medicare and Medicaid Services finalized a rule allowing Medicare Advantage plans to cover certain hemp-derived products. This is another genuine policy win for the medical cannabis and hemp industry.

For seniors and Medicare beneficiaries, this means some health insurance plans can now cover hemp products without Medicare beneficiaries having to pay entirely out of pocket. It's a small opening in the federal insurance architecture for cannabis-adjacent products.

Taken together with the Rohrabacher protection and the FBI hemp memo, there's a pattern here: the federal government is quietly expanding space for medical cannabis and hemp at multiple agencies.

What This Means for Patients and the Industry

For Medical Cannabis Patients

If you're using medical cannabis legally in your state, the Rohrabacher amendment protects you from federal prosecution. That protection just got reaffirmed in Trump's budget proposal. You can continue accessing medical cannabis at dispensaries without the immediate threat of federal raids or prosecutions targeting your state's legal program.

That's not nothing. That's actually important legal certainty for millions of people.

For Cannabis Businesses

Operators in legal states can plan their businesses with more confidence that the federal government won't suddenly use its power to shut down their operations. The budget protection gives another year of certainty. But it's also temporary — it has to be renewed in the next budget cycle.

The industry is still caught between state legality and federal illegality. The Rohrabacher protection makes that limbo more stable, but it doesn't resolve the underlying tension.

For Cannabis Investors

The signal is mixed. On one hand, the budget protection is positive. On the other hand, the stalled rescheduling is frustrating. The messaging is confused. That creates ongoing risk and unpredictability in the cannabis investment space.

Long-term, the cumulative effect of these changes (budget protection, FBI hemp memo, Medicare coverage) suggests the federal government is slowly expanding space for cannabis and hemp within a federally-illegal framework. But "slowly" is the operative word.

The Bigger Picture: Evolution of Federal Cannabis Policy

What we're seeing is not a revolution in federal cannabis policy. It's not legalization. It's not even full federal decriminalization.

What we're seeing is incremental expansion of exceptions to federal prohibition. The Rohrabacher amendment is an exception. The FBI hemp memo is an exception. Medicare coverage of hemp products is an exception.

Over time, if these exceptions accumulate and expand, they create de facto space for cannabis and hemp within a technically-illegal federal framework. It's not clean. It's not ideal. But it works.

The danger is that these protections are always one budget cycle away from being removed. The Rohrabacher amendment gets renewed in spending bills. It's not permanent law. If a different administration wants to shut it down, they can request its repeal and try to include that in a budget.

That's why the cannabis industry continues to push for permanent federal reform — not just temporary budget riders, but actual federal laws that legalize or decriminalize cannabis.

Looking Ahead: What's Next?

The immediate question is whether Congress will include the Rohrabacher-Blumenauer amendment in the actual FY2026 spending bill. Trump's proposal is just that — a proposal. Congress has to appropriate the money. Medical cannabis advocates will almost certainly lobby hard to keep the protection in place.

The longer-term question is what happens with rescheduling. If it moves forward, that's a bigger shift in federal policy. If it stalls indefinitely, that's a different story.

For now, medical cannabis patients and operators can feel somewhat assured that their legal state programs won't face federal interference — at least not through the DOJ's budget. That's real protection, even if it's not permanent or complete.

Bottom Line

Trump's budget proposal including continued protection for state medical cannabis laws is genuinely good news for patients, caregivers, and legal operators in medical cannabis states. It reverses his earlier request to repeal the Rohrabacher-Blumenauer amendment and maintains legal certainty.

But it's also a reminder that federal cannabis policy remains in flux, subject to budget cycles and political whims. The protection is real, but it's also fragile. The work of securing permanent federal reform continues, and industry advocates won't stop pushing until cannabis policy is modernized at the federal level — whether through rescheduling, legalization, or some combination of both.

For now, take the win. Medical cannabis programs are protected. The federal government is quietly expanding space for hemp and CBD. Progress is happening, even if it's not making headlines.

That's actually kind of how real policy change works — quietly, in budget language, through FBI memos and CMS rules, rather than dramatic declarations. Sometimes the biggest shifts are the ones nobody talks about.